‍Reset Health and Super Protocol today announced a new Confidential AI capability for Reset AI within Reset Health’s clinician-led digital care platform for cardiometabolic conditions, including obesity and type 2 diabetes.

Averly Health launches to transform cardiometabolic care in the UK.

Twelve-month IBT persistence in real-world practice commonly falls below 50%. How self-pay vs state-funding may affect IBT persistence has not been fully characterised.

New data being presented today at the 2026 UK Congress on Obesity (UKCO) has shown patients are more likely to stay on medication longer and achieve significant weight loss when enrolled in a specialist digital care service.

Obesity costs the NHS £11.4 billion a year. For the whole economy, that figure rises to £74.3 billion.¹ This is the government’s own estimate, cited in the Health and Social Care Committee’s recent report on obesity and the food environment. 

In as many months, the MHRA has approved two oral GLP-1 tablets for weight management. The first, a semaglutide (known commercially as the Wegovy pill), and more recently orforglipron (sold under the name Foundayo), making the UK the first country in Europe to approve this latest oral GLP-1 medication.

In June 2026, the Department of Health and Social Care Committee took its final evidence session, completing eight months of oral evidence on food and weight management. What emerged is worth pausing on.

Recently, MHRA approved the first oral GLP-1 weight-loss and weight management medication in the UK. The coverage has rightly focused on what this means for access and convenience, but something important is missing from the conversation.  

Obesity costs the NHS £11.4 billion a year and places a significant additional burden on the wider economy through lost productivity and reduced workforce participation. That broader impact has been estimated by NESTA at 2-3% of GDP. 

Last week, the MHRA approved the UK's first oral GLP-1 tablet for weight loss, a semaglutide tablet meeting the regulator's standards for safety, quality and effectiveness. It is the latest in a series of regulatory milestones that have accelerated rapidly in recent years, and it is a timely prompt to look beyond what these medicines can do and ask how they should be delivered.

There is a number that sits at the heart of most NHS commissioning decisions for incretin-based obesity treatment, and it comes from an assumption that patients will escalate through a standard, monthly up-titration schedule to the maximum maintenance dose.

The European Association for the Study of Obesity (EASO) recently published its pharmacological management framework, shifting focus from weight loss to targeted treatment of obesity-related complications. The framework distinguishes 'fat mass disease' (mechanical complications) from 'sick fat disease' (metabolic/inflammatory complications) to guide medication selection.

Financial models for incretin-based therapies for obesity typically assume rigid titration schedules, where patients escalate monthly to the maximum maintenance dose (the ‘standard schedule’). However, clinical practice often requires personalised titration based on individual response.

Real-world adherence to incretin-based therapies for obesity typically lags behind clinical trials data, with typical attrition of 30–40% at six months.

Reset Health appoints precision medicine leader Dr Joanne Hackett to its Board as it moves to establish Therapeutic Optimisation as a new category of healthcare.

The appointment of former Chief Technology Officer at Healthcare Business Solutions further strengthens Reset Health's leadership team as it accelerates platform development and expands its NHS and commercial partnerships

The recognition celebrates Reset Health's partnership with East Suffolk and North Essex NHS Foundation Trust and Suffolk and North East Essex ICB, which has reduced specialist obesity waiting times from over two years to just eight days.

Reset Health, the experts in the personalised management of chronic disease, has entered a strategic partnership with Pharmacy2U, the UK’s largest online pharmacy, to deliver next-generation digital weight management support to patients using weight loss medication across the UK.

Reset Health, the experts in the personalised management of chronic disease, today announces Pinder Sahota has joined the Company as a member of its Advisory Board.

Obesity and depression are deeply interconnected, yet few programmes effectively address both in tandem. The Roczen Programme, developed by Reset Health Ltd., offers a fresh, clinically grounded approach.

Reset Health is pleased to announce that Professor Sir Jonathan Van-Tam has joined Reset Health as a member of its Advisory Board.

Rochelle brings over 20 years of leadership experience in healthcare, spanning clinical innovation, digital transformation, and strategic product development.

Nearly 26% of adult Britons live with obesity and this number is expected to rise to 37% by 2030.

Obesity and type 2 diabetes (T2D) remain major global health challenges. Continuous energy restriction can help people lose weight, but more recently time-restricted eating (TRE) has been shown to be an alternative method for weight loss.

Obesity is a growing problem in the UK, affecting more and more people and putting a strain on both individuals and the healthcare system.

We’re delighted to welcome David Plans who has joined Reset Health as Chief Scientific Officer (CSO).

Reset Health is pleased to announce the appointment of Sarah Le Brocq as its new UK Head of Public Affairs, effective immediately.

Reset Health is excited to announce a strategic long term collaboration with Affidea, the leading pan-European provider of community-based polyclinics, advanced diagnostics and specialist services. 

From reduced productivity and absenteeism to increased healthcare utilisation for associated conditions, obesity creates significant challenges for employers.

The aim of this service evaluation was to assess the impact of the Reset Health programme on weight, metabolic parameters, and other health-related outcomes at 12 and 24 weeks.

Roczen delivers individualised health programmes utilising time-restricted eating and a low refined carbohydrate, moderate protein diet to those with living with overweight, obesity, prediabetes and type 2 diabetes (T2DM).

Before we talk about obesity medications, it’s important to outline what obesity is and what happens inside the body.

We conducted a retrospective, real-world service evaluation. Patients were initiated on a 16-hour TRE plan with low-carbohydrate, moderate-protein dietary guidance.

‍Reset Health and Super Protocol today announced a new Confidential AI capability for Reset AI within Reset Health’s clinician-led digital care platform for cardiometabolic conditions, including obesity and type 2 diabetes.

Averly Health launches to transform cardiometabolic care in the UK.

New data being presented today at the 2026 UK Congress on Obesity (UKCO) has shown patients are more likely to stay on medication longer and achieve significant weight loss when enrolled in a specialist digital care service.

Reset Health appoints precision medicine leader Dr Joanne Hackett to its Board as it moves to establish Therapeutic Optimisation as a new category of healthcare.

The appointment of former Chief Technology Officer at Healthcare Business Solutions further strengthens Reset Health's leadership team as it accelerates platform development and expands its NHS and commercial partnerships

The recognition celebrates Reset Health's partnership with East Suffolk and North Essex NHS Foundation Trust and Suffolk and North East Essex ICB, which has reduced specialist obesity waiting times from over two years to just eight days.

Reset Health, the experts in the personalised management of chronic disease, has entered a strategic partnership with Pharmacy2U, the UK’s largest online pharmacy, to deliver next-generation digital weight management support to patients using weight loss medication across the UK.

Reset Health is pleased to announce the appointment of Sarah Le Brocq as its new UK Head of Public Affairs, effective immediately.

Obesity is a growing problem in the UK, affecting more and more people and putting a strain on both individuals and the healthcare system.

Reset Health, the experts in the personalised management of chronic disease, today announces Pinder Sahota has joined the Company as a member of its Advisory Board.

Reset Health is pleased to announce that Professor Sir Jonathan Van-Tam has joined Reset Health as a member of its Advisory Board.

Rochelle brings over 20 years of leadership experience in healthcare, spanning clinical innovation, digital transformation, and strategic product development.

We’re delighted to welcome David Plans who has joined Reset Health as Chief Scientific Officer (CSO).

Reset Health is excited to announce a strategic long term collaboration with Affidea, the leading pan-European provider of community-based polyclinics, advanced diagnostics and specialist services. 

Nearly 26% of adult Britons live with obesity and this number is expected to rise to 37% by 2030.

Financial models for incretin-based therapies for obesity typically assume rigid titration schedules, where patients escalate monthly to the maximum maintenance dose (the ‘standard schedule’). However, clinical practice often requires personalised titration based on individual response.

Real-world adherence to incretin-based therapies for obesity typically lags behind clinical trials data, with typical attrition of 30–40% at six months.

The European Association for the Study of Obesity (EASO) recently published its pharmacological management framework, shifting focus from weight loss to targeted treatment of obesity-related complications. The framework distinguishes 'fat mass disease' (mechanical complications) from 'sick fat disease' (metabolic/inflammatory complications) to guide medication selection.

Roczen delivers individualised health programmes utilising time-restricted eating and a low refined carbohydrate, moderate protein diet to those with living with overweight, obesity, prediabetes and type 2 diabetes (T2DM).

We conducted a retrospective, real-world service evaluation. Patients were initiated on a 16-hour TRE plan with low-carbohydrate, moderate-protein dietary guidance.

The aim of this service evaluation was to assess the impact of the Reset Health programme on weight, metabolic parameters, and other health-related outcomes at 12 and 24 weeks.

Obesity and type 2 diabetes (T2D) remain major global health challenges. Continuous energy restriction can help people lose weight, but more recently time-restricted eating (TRE) has been shown to be an alternative method for weight loss.

Obesity and depression are deeply interconnected, yet few programmes effectively address both in tandem. The Roczen Programme, developed by Reset Health Ltd., offers a fresh, clinically grounded approach.

Twelve-month IBT persistence in real-world practice commonly falls below 50%. How self-pay vs state-funding may affect IBT persistence has not been fully characterised.

Obesity costs the NHS £11.4 billion a year. For the whole economy, that figure rises to £74.3 billion.¹ This is the government’s own estimate, cited in the Health and Social Care Committee’s recent report on obesity and the food environment. 

There is a number that sits at the heart of most NHS commissioning decisions for incretin-based obesity treatment, and it comes from an assumption that patients will escalate through a standard, monthly up-titration schedule to the maximum maintenance dose.

Recently, MHRA approved the first oral GLP-1 weight-loss and weight management medication in the UK. The coverage has rightly focused on what this means for access and convenience, but something important is missing from the conversation.  

Last week, the MHRA approved the UK's first oral GLP-1 tablet for weight loss, a semaglutide tablet meeting the regulator's standards for safety, quality and effectiveness. It is the latest in a series of regulatory milestones that have accelerated rapidly in recent years, and it is a timely prompt to look beyond what these medicines can do and ask how they should be delivered.

In as many months, the MHRA has approved two oral GLP-1 tablets for weight management. The first, a semaglutide (known commercially as the Wegovy pill), and more recently orforglipron (sold under the name Foundayo), making the UK the first country in Europe to approve this latest oral GLP-1 medication.

Obesity costs the NHS £11.4 billion a year and places a significant additional burden on the wider economy through lost productivity and reduced workforce participation. That broader impact has been estimated by NESTA at 2-3% of GDP. 

In June 2026, the Department of Health and Social Care Committee took its final evidence session, completing eight months of oral evidence on food and weight management. What emerged is worth pausing on.

From reduced productivity and absenteeism to increased healthcare utilisation for associated conditions, obesity creates significant challenges for employers.

Before we talk about obesity medications, it’s important to outline what obesity is and what happens inside the body.